Cellectis (NASDAQ:CLLS) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Cellectis (NASDAQ:CLLS) in a report released on Monday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

Cellectis Stock Performance

NASDAQ CLLS opened at $1.78 on Monday. The firm has a market cap of $98.94 million, a P/E ratio of -1.38 and a beta of 3.09. The company has a quick ratio of 1.92, a current ratio of 1.92 and a debt-to-equity ratio of 0.39. The company’s 50 day moving average is $2.13 and its 200-day moving average is $2.30. Cellectis has a 12-month low of $0.96 and a 12-month high of $3.77.

Cellectis (NASDAQ:CLLS) last issued its earnings results on Tuesday, August 6th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.05. Cellectis had a negative net margin of 401.83% and a negative return on equity of 78.90%. The business had revenue of $9.50 million for the quarter, compared to analysts’ expectations of $6.00 million. Sell-side analysts predict that Cellectis will post -0.54 earnings per share for the current year.

Institutional Investors Weigh In On Cellectis

Several large investors have recently added to or reduced their stakes in the business. XTX Topco Ltd bought a new position in Cellectis in the 2nd quarter worth about $29,000. First Affirmative Financial Network purchased a new position in shares of Cellectis during the third quarter worth about $45,000. Principal Financial Group Inc. grew its holdings in shares of Cellectis by 6.2% during the first quarter. Principal Financial Group Inc. now owns 424,533 shares of the biotechnology company’s stock worth $1,125,000 after purchasing an additional 24,906 shares in the last quarter. Baillie Gifford & Co. raised its stake in Cellectis by 1.3% in the first quarter. Baillie Gifford & Co. now owns 827,248 shares of the biotechnology company’s stock valued at $2,192,000 after purchasing an additional 10,605 shares in the last quarter. Finally, Long Focus Capital Management LLC raised its stake in Cellectis by 2.9% in the second quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock valued at $8,634,000 after purchasing an additional 130,000 shares in the last quarter. Institutional investors own 63.90% of the company’s stock.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.